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The conundrum of hypercalcaemia in malignancy occurring in the
absence of extensive bony metastases was ﬁnally solved in the late
1980s with the identiﬁcation and cloning of PTHrP (parathyroid
hormone-related protein) and the history of this discovery is
summarised by Martin and Suva (1988). Original work in cell lines
and a renal tumour was followed by the identiﬁcation of PRHrP in
a wide variety of malignances (Honda et al, 1988). PTHrP raises
serum calcium and stimulates osteoclast activity, leading to bone
destruction. This seemed to suggest a simple sequence of events,
but malignancy, bony metastasis and hypercalcaemia are linked
by mechanisms more subtle than any single linear chain of cause
and effect. PTHrP shares eight of its ﬁrst 13 amino acids with
PTH (Mangin et al, 1988). This structural homology leads to
shared receptor binding. There are biochemical differences in the
effects of these two hormones. PTHrP is a more potent inhibitor
of caliuria and promoter of phosphaturia than PTH. Circulating
PTHrP is undetectable in health but present in around 80% of
patients with humoral hypercalcaemia. Tissue expression of PTHrP
is far more extensive than PTH, and this is reﬂected in a range of
functions beyond calcium homeostasis (Strewler, 2000). The
presence of PTHrP in the uterus and the stomach, coupled with
its ability to relax smooth muscle, has led to the assertion that,
in these tissues at least, it is PTHrP which is the true physiological
effector molecule (Martin, 1996). The role of PTHrP in placental
calcium transport seems, similarly, to imply far greater functional
importance than that of PTH. It is the role of PTHrP in cartilage
development, however, which may reveal its signiﬁcance to the
progression of malignant disease. When chondrocytes form new
bone they ﬁrst proliferate then produce the basic extracellular
matrix which will be later invaded by cellular components of bone.
The chondrocytes then apoptose. The absence of PTHrP, in PTHrP
knock-out mice, leads to failure of proliferation and early apoptosis
(Amizuka et al, 1996). This protection of chondrocytes from apop-
tosis in the physiological setting is mirrored in cancer, where
transfection of PTHrP into cell lines confers resistance to apoptotic
stimuli (Dougherty et al, 1999).
PTHrP stimulates osteoclastic bone resorption. Studies in breast
cancer have shown that PTHrP is expressed in most breast
primaries and bony metastases, but to a lesser extent in visceral
metastases (Powell et al, 1991). The question then arises whether
PTHrP is not merely a marker for bony metastases but also prog-
nostic factor for progression. Animal experiments using a PTHrP-
expressing cell line and blocking monoclonal antibody have
demonstrated the importance of PTHrP in progression to meta-
static bone disease (Guise et al, 1996), while cell culture work
indicates that PTHrP can function as a transforming growth factor.
There is, then, a high index of suspicion in breast cancer that
PTHrP is a key factor in the development of bony metastases.
Prostate cancer has a different natural history to breast cancer.
Hypercalcaemia is uncommon in prostate cancer and metastases
are predominantly osteoblastic. It is important to realise, however,
that the osteoblastic response seen in prostate cancer is preceded, at
a cellular level, by osteoclast activation. The difference between
breast and prostate, therefore, is not that osteoclast activation
occurs or does not occur, but rather that in prostatic metastases
an intense osteoblastic reaction is also present (Roodman, 2001).
Elegant experiments using in vivo inocculation of paired transfected
and untransfected cell lines have, furthermore, indicated a greater
metastatic potential for the transfected lines (Rabbani et al, 1999)
mirroring the results in breast cancer.
The paper by Bryden et al. (2002) in this issue of the journal
extends observations of PTHrP expression in other tumours to
prostate cancer. The authors have demonstrated a high rate of
concordance for the expression of both PTHrP and its receptor
in paired primary tumours and bony metastases. The ultimate
purpose of studies such as these is either to identify new markers
of prognostic importance, or to provide a mechanistic explanation
of disease progression which may yield new therapeutic targets.
The high frequency of expression in primary prostate cancers
would seem to indicate that PTHrP is a poor discriminator of
metastatic potential. However, the sample sizes are small, and
larger studies linking PTHrP expression to outcome are required
to demonstrate any prognostic signiﬁcance of this observation.
The role of experimental therapeutics directed against PTHrP
may seem nonsensical, since the numerous factors which come into
play by the time metastatic bone disease has developed implies that
there is no role for PTHrP-directed intervention. If, however, a link
between PTHrP and progression to bone disease is established,
then targetting the PTHrP at earlier disease stages might eventually
lead to a change in the natural history of prostate cancer.
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